Overview

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the safety and efficacy of combination chemotherapy with Pazopanib in pediatric patients with relapsed/refractory solid tumor
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Samsung Medical Center
Collaborator:
Ministry of Health, Republic of Korea
Treatments:
Carboplatin
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Criteria
Inclusion Criteria:

- Patients with refractory/relapsed solid tumor (Stable or progressive disease after
1st-line treatment or relapse)

- Patients previously enrolled to "Genomic diagnosis of pediatric tumors by NGS (IRB No.
SMC 2015-11-053)"

Exclusion Criteria:

- Patients who had high-dose chemotherapy and autologous stem cell transplantation
previously

- Patients with organ dysfunction as follows (creatinine elevation ≥ 1.5 x upper limit
of normal (ULN), ejection fraction <40%, significant arrhythmia or conduction
disturbance)

- Patients who are not eligible to have scheduled treatment due to the other significant
impaired organ function

- Patients with active bleeding

- Patients who are taking strong CYP3A4 inhibitors, QTc-prolonging drugs, antithrombotic
agents, or anti-platelet agents

- Pregnant or nursing women

- Patients who can not swallow the pill